The genes involved in the serotonin system are major candidates in association studies on affective disorders and responses to antidepressants. We studied a functional polymorphism of the serotonin transporter (5-HTT) gene (a 44 bp insertion/deletion in the 5-HTT-linked polymorphic region (5-HTTLPR)) and lifetime history of antidepressant-induced mania (AIM) in a population of 305 patients with bipolar affective disorder. AIM was defined using a broad definition and a restrictive definition. No association was found between the 's' allele of the 5-HTTLPR and AIM for either definition. However, we found an association between the 5-HTTLPR and lifetime history of rapid cycling in a subsample of patients (for allele and genotype distributions: exact probability, p ¼ 0.0009 and w 2 ¼ 9.4; df ¼ 1; p ¼ 0.002, respectively). These results may help to explain the conflicting association results obtained with the 5-HTT gene polymorphism, in particular with AIM. Indeed, the precise phenotype associated with the 5-HTT gene is unclear. The association between the 's' allele and rapid cycling may provide further evidence for an association between the 5-HTTLPR 's' allele and a pattern of affective instability.
INTRODUCTION
Bipolar affective disorder (BPAD) affects 1-2% of the population and the clinical course can be extremely variable. 1 Clinicians managing depression in patients with BPAD face two challenges. First, major depression is a handicapping disease and is associated with a high risk of suicide in bipolar patients. 2 Second, in bipolar patients, antidepressant drugs are associated with a high risk of antidepressant-induced mania (AIM) and rapid cycling. The identification of predictors of AIM is a key issue for the therapeutic management of bipolar patients. Clinical studies on bipolar patients with and without AIM have identified characteristics with poor sensitivity and low specificity.
The genes involved in the serotonin system are major candidates in association studies on affective disorders and responses to antidepressants. The serotonin transporter (5-HTT) gene encodes the protein responsible for the reuptake of serotonin from the synapse after its release from serotonergic neurons. In this case-control study, we investigated whether this gene is a susceptibility factor for AIM and rapid cycling, two major complications of the use of antidepressants in bipolar patients. We studied a functional polymorphism of the 5-HTT gene (a 44 bp insertion/deletion in the 5-HTT-linked polymorphic region (5-HTTLPR)) and lifetime history of AIM in a population of 305 patients with BPAD. Based on the results of several recent studies, we hypothesized that AIM is related to this functional genetic polymorphism. Several studies have demonstrated that the 5-HTT gene polymorphism plays a role in the antidepressant response. [3] [4] [5] [6] [7] In addition, Mundo et al 8 reported a significant association between the 5-HTTLPR and AIM in bipolar patients treated with proserotonergic compounds. However, the interpretation of this study was limited by the absence of a consensus definition of AIM.
No clear definition of AIM is available in the literature or in international classification systems. We used two definitions of AIM: (i) a broad definition, similar to that used by Mundo et al, 8 to classify bipolar patients and (ii) a narrow (more restrictive) definition to determine whether these bipolar patients also suffered from AIM (during a limited period of time after antidepressant prescription), despite treatment with several antidepressants but without coprescription of mood stabilizers.
Patients with AIM were treated with serotonergic and nonserotonergic compounds. To try to replicate the association reported by Mundo et al, we also performed an association test in the subsample of patients treated with proserotonergic antidepressants.
RESULTS
For both definitions, we only selected subjects who were informative for a positive or a negative history of AIM. According to the broad definition of AIM, 83 patients were AIM(+) and 149 were AIM(À). According to the restrictive definition of AIM, 76 patients were AIM(+) and 58 were AIM(À). The clinical characteristics of the AIM(+) and AIM(À) patients are described in Table 1 (Table 3) .
No association was detected in the subsample of patients treated with proserotonergic antidepressants (for genotype distribution, w 2 ¼ 0.29; df ¼ 2; p ¼ 0.86)(data not shown). A total of 237 patients were informative with regard to the existence of a lifetime history of rapid cycling according to the DSM-IV criteria. In all, 19 bipolar patients in our sample had a lifetime history of rapid cycling whereas 181 did not. Allele and genotype distributions differed significantly between patients with and without rapid cycling (exact probability, p ¼ 0.0009 and w 2 ¼ 9.4; df ¼ 1; p ¼ 0.002, respectively) ( Table 4) .
In this sample, there was no significant association between AIM (the broad or the narrow definition) and rapid cycling (exact probability, p ¼ 0.068 and 0.11, respectively).
DISCUSSION
For both definitions of AIM, the frequency of the 's' allele was higher in patients with AIM(+) than in those without AIM, but this difference was not significant. We did not replicate the association reported by Mundo et al 8 between the 's' allele of the 5-HTTLPR and AIM in Canadian patients. According to the broad definition, the presence or absence of AIM could not be determined in 10 subjects.
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Our sample (at least 76 patients with AIM and 58 without AIM) provides a power of more than 90% for the detection of an association of the magnitude of that reported by Mundo et al. 8 It is thus unlikely that our negative result can be explained by a lack of power. There are several other possible reasons for these conflicting results. First, there may be genetic heterogeneity between Canadian and European patients. If AIM is associated with another polymorphism within the 5-HTT gene or within another nearby gene, the linkage disequilibrium between the 5-HTTLPR and this vulnerability polymorphism may vary across populations. Second, the result reported by Mundo et al 8 may be because of an ethnic stratification bias, leading to a false-positive result. Phenotypic uncertainties may also have contributed to the lack of reproducibility. Indeed, the absence of a clear definition of AIM may have contributed to these conflicting results. To try to overcome this potential methodological problem, we used two definitions of AIM. Despite this precaution, we found no association with either definition. With regard to phenotype uncertainties, it may be important to consider the type of antidepressant used. Mundo et al included patients treated with proserotonergic antidepressants. In our subsample of similar patients, no association was detected.
It has been suggested that there is a clinical link between rapid cycling and AIM. [9] [10] [11] The association that we observed between rapid cycling and the 5-HTTLPR may be related to the result obtained by Mundo et al. Indeed, patients with rapid cycling may be over-represented among AIM(+) patients and under-represented among AIM(À) patients. Mundo et al only evaluated the presence of rapid cycling in the previous 12 months, whereas we considered the lifetime history of rapid cycling. However, this association between rapid cycling and the 5-HTTLPR needs to be replicated in independent samples and in samples of bipolar patients prospectively evaluated.
Tricyclic antidepressants (TC) are the most likely to induce AIM. The discrepancies between our results and those reported by Mundo et al are probably not because of the fact that TCs were frequently prescribed in the Canadian population. Indeed, TCs were more frequently prescribed in our sample than in the Canadian one. However, differences in the daily dose of selective serotonin reuptake inhibitors (SSRI) and/or plasma concentrations may account for the differences observed between the Canadian sample and our European sample. Indeed, it has been reported that SSRIs induce AIM in a dose-dependent manner. 12 Several independent associations have been reported between the 's' allele and anxiety disorders, violent suicidal behavior, [13] [14] [15] seasonal affective disorder 16 and rapid cycling (this study). These results, together with the association reported by Mundo et al 8 and the association between the 's' allele and rapid cycling (this study), suggest that there is an association between the 5-HTTLPR 's' allele and a pattern of affective instability. This pattern of instability may be a common underlying phenotype. The possibility that rapid cycling could be induced by antidepressant treatment should also be considered. Further studies on independent samples are needed to identify the precise phenotype associated with the 5-HTTLPR and to explain how the 5-HTTLPR affects the phenotypic expression of BPAD.
MATERIALS AND METHODS
A total of 305 patients who met the DSM-IV criteria for bipolar disorder were prospectively recruited (202 in France and 103 in Switzerland) and included in this study after giving informed consent. The patients were all Caucasians. The patients were recruited from university-based departments of adult psychiatry in Switzerland (Geneva) and in France (Albert Chenevier, Henri Mondor and Pitié Salpê-trière Hospitals, Paris and the Charles Perrens Hospital, Bordeaux). Patients were interviewed by trained psychiatrists and psychologists, using the French version of the Diagnostic Interview for Genetic Studies. 17 DNA was isolated from peripheral blood leukocytes by standard procedures. The insertion/deletion polymorphism in the 5-HTTLPR was amplified by PCR with the following primers: 5 0 -GGC GTT GCC GCT CTG AAT C-3 0 (forward, strp5) and 5 0 -GAG GGA CTG AGC TGG ACA ACC AC-3 0 (reverse, strp3). 18 The region was amplified using standard protocols, except that dGTP was replaced by 7-deaza-dGTP. The optimal annealing conditions for the intron 2 polymorphism were 591C for 30 cycles. For the 5-HTTLPR polymorphism, the annealing conditions were as follows: 631C for two cycles, 621C for two cycles and 611C for 34 cycles. The PCR products were subjected to electrophoresis in an 8% polyacrylamide gel and silver stained. Allele sizes were determined by comparing the bands with size standards. Amplification of the 5-HTTLPR resulted in two alleles (l and s) differing by 44 base pairs (bp). 
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Two definitions of AIM were used:
(1) A broad definition, similar to that used by Mundo et al. 8 All DSM-IV bipolar subjects who reported having experienced an episode of elevated mood and excitation after the introduction of antidepressant treatment were diagnosed as having a positive history of AIM (AIM(+)). The coprescription of a mood stabilizer and the duration of its use were not considered in this definition.
(2) Patients were also classified according to a more restrictive definition. Only patients who reported an episode of elevated mood and excitation in the 90 days after the beginning of an antidepressant treatment were diagnosed as AIM(+). According to this definition, patients were AIM(À) if they had had at least two major depressive episodes treated by antidepressants without a mood stabilizer and without an elevated mood and excitation in the 90 days following the prescription of the antidepressant.
Patients in the AIM(+) group (broad definition) were treated with TC (n ¼ 28), selective serotonin reuptake inhibitors (n ¼ 27), venlafaxine (n ¼ 6), mirtazapine (n ¼ 1), moclobemide (n ¼ 2), nomifensine (n ¼ 1), trazodone (n ¼ 1) and amineptine (n ¼ 6) during the development of a manic or a hypomanic episode. Several of the bipolar patients in this group had more than one AIM episode. In addition, the ongoing treatment consisted of an association of two antidepressants for six AIM(+) patients and three antidepressants for one AIM(+) patient. The exclusion criteria were the same as those described by Mundo et al. 8 Rapid cycling was defined as the lifetime existence of a period of at least 1 year with at least four thymic episodes (depressive, hypomanic or manic) per year.
The allele and genotype distributions of the patients were compared by use of the w 2 test. For contingency tables containing a small number of subjects (less than five), the exact probability was calculated by the CLUMP program (1000 simulations). 19 A significance threshold of po 0.05 was used.
